BRAF and melanoma: Therefore, we propose that combining dabrafenib, trametinib, and an IGF1R/IR inhibitor in patients with BRAF-mutant melanoma who have relapsed or dabrafenib and trametinib therapy regimen could be an effective strategy and warrants further investigation in the clinic.